GlaxoSmithKline LLC

Initial pilot study data validate feasibility and applicability of HERC in advancing equitable cancer care delivery at leading cancer centers. MINNEAPOLIS, Oct. 28, 2024 /PRNewswire/ -- Today, the National Comprehensive Cancer Network® (NCCN®) is presenting preliminary data from a study evaluating the usability of the Health Equity Report Card (HERC) tool during the American Public Health Association (APHA) Annual Meeting and Expo. Continue Reading The HERC was created by the Elevating Cancer Equity collaboration between NCCN, the American Cancer Society Cancer Action Network (ACS CAN), and the National Minority Quality Forum (NMQF) and updated by a subsequent working group. It features 19 practice evaluation and change recommendations designed to help providers and healthcare organizations identify and address disparity and bias in care delivery, address social determinants of health, and overcome systemic barriers to optimal care. "[This demonstrates] the HERC's potential as a transformative tool for measuring and improving equity in cancer care." Post this All 19 Health Equity Report Card (HERC) recommendations can be found at NCCN.org/HERC. The study abstract is available at APHA's website at . "Studies clearly show that unequal experiences and opportunities in cancer care result in worse outcomes and shorter life-expectancies for people in underserved communities," stated Taneal D. Carter, MS, MPA, Manager, NCCN Cancer Care Equity Program. "The HERC was initially designed as an objective approach to increase equity in cancer care through attainable and measurable change. This initial pilot study data illustrates just how attainable these goals really are. We are proud to announce that every participating site reported HERC implementation would either inform or reinforce necessary changes in institutional practices and processes." The Health Equity Report Card (HERC) measures care systems' equitable practices across 4 domains: Community Engagement Accessibility of Care and Social Determinants of Health Addressing Bias in Care Delivery Quality and Comprehensiveness of Care The pilot study focused on gathering feedback from five leading academic cancer centers, to gauge the feasibility and usability of the HERC tool. Pre-implementation surveys showed that three of the five cancer centers anticipated challenges in implementing the tool, but all five centers successfully completed a first round of self- and third-party scoring across all domains. Every site strongly agreed or agreed that HERC performance measures, metrics, and sources of evidence were applicable to their institution. "These preliminary findings demonstrate the HERC's usability and underscore its potential as a transformative tool for measuring and improving equity in cancer care," said Crystal S. Denlinger, MD, Chief Executive Officer, NCCN. "We are happy to be able to share this initial data, showcasing how participating sites found the HERC's performance measures to be relevant to their institutions. We look forward to additional analysis of the data and ongoing feedback to further improve the utility of this tool." An article with full results following the first round of scoring—including a subsequent score and improved scorecard—will be publishing in the coming months. Additional evaluation is underway into the HERC's scoring, feedback mechanisms, and impact on cancer care, including a separate pilot project conducted in the community cancer center setting. The HERC pilot program at academic cancer centers is made possible through support from AbbVie Inc.; 2seventy bio; Genentech, Inc.; Lilly; and Sanofi Genzyme. The HERC Community Project is part of the Alliance for Equity in Cancer Care, made possible through support from the Merck Foundation. It is also supported by contributions from Bristol Myers Squibb; GlaxoSmithKline LLC; Lilly; and Pfizer Inc. Visit NCCN.org/equity to learn more about NCCN's ongoing work to improve equity in cancer care. About the National Comprehensive Cancer Network The National Comprehensive Cancer Network® (NCCN ®) is a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to improving and facilitating quality, effective, equitable, and accessible cancer care so all patients can live better lives. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ®) provide transparent, evidence-based, expert consensus recommendations for cancer treatment, prevention, and supportive services; they are the recognized standard for clinical direction and policy in cancer management and the most thorough and frequently-updated clinical practice guidelines available in any area of medicine. The NCCN Guidelines for Patients® provide expert cancer treatment information to inform and empower patients and caregivers, through support from the NCCN Foundation®. NCCN also advances continuing education, global initiatives, policy, and research collaboration and publication in oncology. Visit NCCN.org for more information. Media Contact: Rachel Darwin 267-622-6624 [email protected] SOURCE National Comprehensive Cancer Network WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

James Huang brings over 30 years of biotech experience as a successful entrepreneur, investor and key opinion leader in the healthcare sector SAN DIEGO, CA and TAICANG, China, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, announced today the appointment of James Zuie-chin Huang, M.B.A., to its Board of Directors effective immediately. James Huang is the Founder and Managing Partner of Panacea Venture, a significant shareholder of the Company. “We are thrilled to welcome James to Connect’s Board of Directors,” said Wubin (Bill) Pan, Ph.D., M.B.A., Co-Founder, President, and Chairman of the Board of Connect Biopharma. “His breadth of biotech and investment experience, coupled with his passion for innovative and transformative life science companies will provide our Board with a unique perspective. We look forward to leveraging his deep industry insights as we continue to advance our robust pipeline of best-in-class potential therapies.” “I am pleased to join Connect Biopharma’s Board of Directors at this exciting time for the company following the two positive readouts for rademikibart in atopic dermatitis and asthma,” commented James Huang, M.B.A. “I look forward to working with my fellow board members and Connect Biopharma’s leadership to advance rademikibart’s development and the broader pipeline of highly differentiated therapeutic candidates.” Mr. Huang has over 30 years of biotech experience and is the Founder and Managing Partner of Panacea Ventures. Prior to Panacea, Mr. Huang was a Managing Partner at Kleiner Perkins (KPCB) China where he focused on the firm’s life sciences practice, and a managing partner at Vivo Ventures where he led numerous investments in China. He was also the president of Anesiva, a biopharmaceutical company focused on pain-management treatments. Earlier in his career, he held senior roles in business development, sales, marketing, and R&D with Tularik Inc. (acquired by Amgen), GlaxoSmithKline LLC, Bristol-Myers Squibb and ALZA Corp. (acquired by Johnson & Johnson). Additionally, Mr. Huang serves as a director on the board of directors of a number of companies, including Kindstar Global, TacTiva Therapeutics, TriArm Therapeutics, Chime Biologics, Eos, GT Aperion, Domain, Asia Pacific Medical and XWPharma. He received an M.B.A. from the Stanford Graduate School of Business and a B.S. degree in chemical engineering from the University of California, Berkeley. About Connect Biopharma Holdings Limited Connect Biopharma is a global, clinical-stage biopharmaceutical company applying its expertise in T cell biology and deep knowledge of the drug discovery industry to develop innovative therapies to treat chronic inflammatory diseases with the goal of improving the lives of millions of those affected around the world. The Company is building a rich pipeline of proprietary small molecules and antibodies, using functional T cell assays, to screen and discover potent product candidates against validated immune targets. The Company’s lead product candidate, rademikibart (formerly known as CBP-201), is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. The Company’s second product candidate, icanbelimod (formerly known as CBP-307), is a modulator of S1P1 T cell receptors and is in development for the treatment of ulcerative colitis (UC). The Company’s third product candidate, CBP-174, is a peripherally acting antagonist of histamine receptor 3, in development for the treatment of pruritus associated with AD. For more information, please visit: https://www.connectbiopharm.com/ Forward-Looking Statements Connect Biopharma cautions that statements included in this release that are not a description of historical facts are forward-looking statements. Words such as “may,” “could,” “will,” “would,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “intend,” “predict,” “seek,” “contemplate,” “look forward,” “potential,” “continue” or “project” or the negative of these terms or other comparable terminology are intended to identify forward-looking statements. These statements include the Company’s plans to advance the development of its product candidates including rademikibart, the timing of achieving any development, regulatory or commercial milestones or reporting data or whether such milestones or data will be achieved or generated, including whether any new drug application will be submitted or accepted and the timing thereof, and the potential of such product candidates, including to achieve any benefit, improvement, differentiation, trend or profile or any product approval or be effective. The inclusion of forward-looking statements should not be regarded as a representation by Connect Biopharma that any of its plans will be achieved. Actual data may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company’s business and other risks described in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 20-F filed with the SEC on April 11, 2023, and its other reports. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Connect Biopharma undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof. Further information regarding these and other risks is included in Connect Biopharma’s filings with the SEC which are available from the SEC’s website (www.sec.gov) and on Connect Biopharma’s website (www.connectbiopharm.com) under the heading “Investors.” All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995. INVESTOR CONTACT:Tim McCarthyLifeSci Advisorstim@lifesciadvisors.com

WASHINGTON, May 15 (Reuters) - The U.S. Supreme Court on Monday declined to hear Teva Pharmaceuticals USA Inc's (TEVA.TA) challenge to a $235 million award to GlaxoSmithKline LLC (GSK.L) in a patent dispute over generic drugs involving a heart medication. The justices turned away Israel-based Teva's appeal of a lower court's ruling reinstating the jury award for U.K.-based GSK. The case involves "skinny labels," which allow generic drugmakers to avoid patent lawsuits if a generic drug's label omits potentially infringing uses of a brand-name drug. GSK sued Teva in Delaware federal court in 2014 over its generic version of GSK's heart drug Coreg. Teva argued that it followed U.S. Food and Drug Administration instructions to "carve out" from its label a patented method for using the drug to treat heart failure. A jury awarded GSK $235 million in 2017. A judge then overturned the verdict, but the patent-focused U.S. Court of Appeals for the Federal Circuit reinstated it in 2020. The Federal Circuit affirmed after a rehearing last year that Teva's label, combined with its marketing materials, encouraged doctors to prescribe the generic in a way that constituted patent infringement. Teva, in its appeal, told the Supreme Court that the ruling would cause "havoc" and discourage the use of skinny labels, which it said are "extraordinarily common" and "save patients and the federal government billions." President Joe Biden's administration also urged the Supreme Court to hear the case, arguing that the Federal Circuit's decision created "significant uncertainty" for generic drugmakers. GSK responded in a court brief that the case "presents no threat to generic companies who operate properly under the law." A Teva spokesperson said the company was disappointed with the Supreme Court's decision but has other defenses it will present at the Delaware court. A GSK spokesperson said the company was pleased with the decision. Our Standards: The Thomson Reuters Trust Principles. Thomson Reuters Blake Brittain reports on intellectual property law, including patents, trademarks, copyrights and trade secrets, for Reuters Legal. He has previously written for Bloomberg Law and Thomson Reuters Practical Law and practiced as an attorney. Contact: 12029385713